A Phase 1b Study of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product in Patients With Locally Advanced or Metastatic Breast Cancer.
Phase of Trial: Phase I
Latest Information Update: 01 Dec 2016
At a glance
- Drugs Docetaxel (Primary) ; Ramucirumab (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors Eli Lilly
- 01 Nov 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Sep 2012 Planned End Date changed from 1 Sep 2012 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 04 Jun 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.